HomeInsightsStock Comparison

Biocon Ltd vs Granules India Ltd Stock Comparison

Biocon Ltd vs Granules India Ltd Stock Comparison

Last Updated on: May 04, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 318.65 as of 02 May 15:30.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 31 on March 2024 . This represents a CAGR of -6.51% over 5 yearsThe P/E Ratio of Granules India Ltd changed from 10.9 on March 2020 to 25.7 on March 2024 . This represents a CAGR of 18.71% over 5 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 31707 crore on March 2024 . This represents a CAGR of -0.48% over 5 yearsThe Market Cap of Granules India Ltd changed from ₹ 3650 crore on March 2020 to ₹ 10420 crore on March 2024 . This represents a CAGR of 23.34% over 5 years.
  • The revenue of Biocon Ltd for the Dec '24 is ₹ 3874 crore as compare to the Sep '24 revenue of ₹ 3648 crore. This represent the growth of 6.18% The revenue of Granules India Ltd for the Dec '24 is ₹ 1143 crore as compare to the Sep '24 revenue of ₹ 969.87 crore. This represent the growth of 17.89%.
  • The ebitda of Biocon Ltd for the Dec '24 is ₹ 804.7 crore as compare to the Sep '24 ebitda of ₹ 743.9 crore. This represent the growth of 8.17% The ebitda of Granules India Ltd for the Dec '24 is ₹ 235.97 crore as compare to the Sep '24 ebitda of ₹ 206.57 crore. This represent the growth of 14.23%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 81.1 crore over 7 quarters. This represents a CAGR of -29.33% The net profit of Granules India Ltd changed from ₹ 47.9 crore to ₹ 117.6 crore over 7 quarters. This represents a CAGR of 67.07% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 50.32 % on March 2024 . This represents a CAGR of -10.30% over 3 yearsThe Dividend Payout of Granules India Ltd changed from 5.72 % on March 2020 to 8.34 % on March 2024 . This represents a CAGR of 7.83% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Granules India Ltd

  • Granules India Limited is a large-scale vertically integrated company founded in March 18th, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
  • With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
  • The company has a global presence across over 80 countries servicing over 300 customers.
  • Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies.
  • The company has one of largest PFI and single site FD facilities in the world.

Biocon Ltd News Hub

News

Biocon's board OKs to raise Rs 4,500-cr

'Raising of funds by way of issuance any instrument or security, including equity shares, ...

Read more

24 Apr 2025 08:11

News

Board of Biocon approves fund raising up to Rs 4,500 cr

The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up ...

Read more

23 Apr 2025 20:05

News

Biocon to consider fund Raising

Biocon will hold a meeting of the Board of Directors of the Company on 23 April 2025. Powe...

Read more

21 Apr 2025 09:37

News

Biocon surges on U.S. deal for Eylea copycat drug

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating...

Read more

15 Apr 2025 09:58

News

Board of Biocon approves CP issuance of Rs 600 cr

The Board of Biocon at its meeting held on 04 April 2025 has approved issuance of Commerci...

Read more

05 Apr 2025 14:34

News

Biocon to table results

Biocon will hold a meeting of the Board of Directors of the Company on 8 May 2025. Powered...

Read more

03 Apr 2025 09:49

Granules India Ltd News Hub

News

Granules India completes acquisition of Swiss-based CDMO - Senn Chemicals AG

Granules India announced the successful closing of the acquisition of Senn Chemicals AG, a...

Read more

11 Apr 2025 10:15

News

Granules India allots 50,000 equity shares under ESOS

Granules India has allotted 50,000 equity shares under ESOS on 20 March 2025. Powered by C...

Read more

20 Mar 2025 19:46

News

Granules India Ltd Falls 3.02%

Granules India Ltd lost 3.02% today to trade at Rs 457.2. The BSE Healthcare index is down...

Read more

05 Mar 2025 09:30

News

Granules India announces cessation of Senior VP and Head - API Manufacturing and Operations

Granules India announced that Sethu Madhavan Sankaran, shall cease to be the Senior Manage...

Read more

28 Feb 2025 14:19

News

Granules India rises after board OKs to acquire 100% stake in Senn Chemicals AG

Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactur...

Read more

24 Feb 2025 12:26

News

Granules India's board OKs to acquire 100% stake in Senn Chemicals AG

Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactur...

Read more

22 Feb 2025 08:56

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Granules India Ltd

Strength

4

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Granules India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Granules India Ltd

Which company has a larger market capitalization, Biocon Ltd or Granules India Ltd?

Market cap of Biocon Ltd is 38,257 Cr while Market cap of Granules India Ltd is 11,049 Cr

What are the key factors driving the stock performance of Biocon Ltd and Granules India Ltd?

The stock performance of Biocon Ltd and Granules India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Granules India Ltd?

As of May 4, 2025, the Biocon Ltd stock price is INR ₹318.65. On the other hand, Granules India Ltd stock price is INR ₹455.55.

How do dividend payouts of Biocon Ltd and Granules India Ltd compare?

To compare the dividend payouts of Biocon Ltd and Granules India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions